Stockreport

INO-3107 At The Crossroads: FDA Review Drives Inovio's Upside And Risk [Seeking Alpha]

Inovio Pharmaceuticals, Inc.  (INO) 
NASDAQ:AMEX Investor Relations: ir.inovio.com/investors/default.aspx
PDF The FDA accepted the BLA for INO-3107 but cited insufficient justification for accelerated approval, introducing significant regulatory risk ahead of the October 30 PDU [Read more]